Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Surgical Innovations Group plc (LSE:SUN) has reported consistent revenue performance for 2024, complemented by a robust start to 2025 that sets the stage for renewed growth. While adjusted EBITDA saw a modest decline and adjusted EPS remained negative, the company posted gains in sales of its own-branded SI products and maintained strong momentum in its OEM business.
The recent launch of the LogiTube™ product line, along with several new distribution agreements, has expanded the company’s footprint—particularly within the obesity surgery segment. Strategic initiatives to reduce operating costs and streamline efficiencies are currently underway, aimed at improving profitability over the coming year.
Surgical Innovations has also reinforced its presence in the UK through fresh distribution partnerships, reinforcing its domestic market strength while exploring new avenues for international growth. Management remains focused on leveraging innovation and operational improvements to drive better results in 2025 and beyond.
About Surgical Innovations Group plc
Surgical Innovations Group designs and manufactures advanced medical devices for minimally invasive procedures. Its product portfolio includes port access systems, retraction devices, and precision surgical tools. Headquartered in the UK, the company sells both domestically and internationally, with a strong emphasis on sustainable innovation through its unique “resposable” model—a hybrid of reusable and disposable components. Surgical Innovations also holds exclusive UK distribution rights for select specialist surgical products, supporting its mission to deliver efficient and environmentally responsible surgical solutions.
